- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
p53 Antibody Phospho (pS392)Rabbit Monoclonal Antibody
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AJ1573g | 100ul 400 ul | 2-3 days | $ 355.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
p53 Antibody Phospho (pS392) - Product info | |
| Application | WB, IHC, IF
|
| Primary Accession | P04637 |
| Reactivity | Human, Rat |
| Clone Names | EP155Y |
| Calculated MW | 43653 Da |
| Gene ID 7157 | |
| Other Names TP53, P53, Cellular tumor antigen p53, Tumor suppressor p53;Phosphoprotein p53;Antigen NY-CO-13 | |
| Target/Specificity A synthetic peptide corresponding to residues in the C-term of human Ubiquitin was used as immunogen. The antibody will detect p53 phosphorylation on Serine 392. | |
| Dilution WB~~1:1000 IHC~~1:100~250 | |
| Format 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions p53 Antibody Phospho (pS392) is for research use only and not for use in diagnostic or therapeutic procedures. | |
p53 Antibody Phospho (pS392) - Protein Information | |
| Name TP53 | |
| Synonyms P53 | |
| Function Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; te function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA- Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis | |
| Cellular Location Cytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Note=Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2. Translocates to mitochondria upon oxidative stress Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli | |
| Tissue Location Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine | |
p53 Antibody Phospho (pS392) - Related products
AP3199a: Phospho-p53-S20 Antibody
AP3200a: Phospho-p53-S315 Antibody
AP3201a: Phospho-P53-S33 Antibody
AP3202a: Phospho-P53-S37 Antibody
AP3203a: Phospho-p53-S376 Antibody
AP3204a: Phospho-p53-S378 Antibody
AP3206a: Phospho-P53-S9 Antibody
AP3207a: Phospho-p53-T18 Antibody
AP3491a: Phospho-p53-S46 Antibody
AP3492a: Phospho-p53-T55 Antibody
AP6266b: p53 Antibody (C-term)
BP3199a: Phospho-p53-S20 Antibody Blocking Peptide
BP3200a: Phospho-p53-S315 Antibody Blocking Peptide
BP3201a: Phospho-P53-S33 Antibody Blocking Peptide
BP3202a: Phospho-P53-S37 Antibody Blocking Peptide
BP3203a: Phospho-p53-S376 Antibody Blocking Peptide
BP3204a: Phospho-p53-S378 Antibody Blocking Peptide
BP3206a: Phospho-P53-S9 Antibody Blocking Peptide
BP3207a: Phospho-p53-T18 Antibody Blocking Peptide
BP3491a: Phospho-p53-S46 Antibody Blocking Peptide
BP3492a: Phospho-p53-T55 Antibody Blocking Peptide
BP6266b: p53 Antibody (C-term) Blocking Peptide
BP6266d: p53 Antibdoy (T55) Blocking Peptide
BP6266e: p53 Antibdoy (S15) Blocking Peptide
BP6266f: p53 Antibody (S37) Blocking Peptide
BP6266g: p53 Antibody (S46) Blocking Peptide
BP6266h: p53 Antibody (S315) Blocking Peptide
AT4310a: TP53 Antibody (monoclonal) (M01)
AJ1573b: p53 Antibody (C-term)
AJ1573c: p53 Antibody (N-term)
AJ1573d: p53 Antibody Acetyl (K382)
AJ1573e: p53 Antibody Acetyl (K373)
AJ1573f: p53 Antibody Phospho (pS33)
AJ1573g: p53 Antibody Phospho (pS392)
AJ1573h: p53 Antibody Phospho (pS392)
AJ1573i: p53 Antibody Phospho (pS46)
p53 Antibody Phospho (pS392) - Application data
-
A. Western blot analysis on MCF7 cell lysate using anti-phospho-p53 (pS392) RabMAb (Cat. #AJ1573g), 1:500 dilution. Cells were either (A) non treated or treated with Actinomycin D for (B) 3 hrs, (C) 6 hrs, and (D) 18hrs
-
B. Immunohistochemical analysis of paraffin-embedded human prostate adenocarcinoma using anti-p53 (pS392) RabMAb (Cat. #AJ1573g)
-
C. Immunofluorescent staining of A431 cells using anti-p53 (pS392) RabMAb (Cat. #AJ1573g)
p53 Antibody Phospho (pS392) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
p53 acts as both a tumor-suppressor and transcription factor that, upon activation by DNA damage and other cellular stress signals, leads to the transcription of genes triggering cell-cycle arrest, apoptosis, and DNA repair (1,2). The gene for the nuclear phosphoprotein p53 is the most commonly mutated gene yet identified in human cancers (3). p53 is frequently mutated or inactivated in about 60% of cancers (4,5).
REFERENCES
1. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88: 323
2. Lakin, N.D. and S.P. Jackson. Regulation of p53 in response to DNA damage. Oncogene 18: 7644
3. Vogelstein, B. Cancer. A deadly inheritance. Nature 348: 681
4. Hoolstein, M., et al. p53 mutations in human cancers. Science 253: 49
5. Harris C.C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980
